Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
NCT ID: NCT00499655
Last Updated: 2017-03-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
107 participants
INTERVENTIONAL
2007-11-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase II trial is studying how well giving erlotinib hydrochloride together with celecoxib works compared with erlotinib hydrochloride alone in treating patients with stage IIIB-IV non-small cell lung cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
NCT00062101
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00556712
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00416650
Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT01708954
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00661193
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Comparison of progression-free survival (PFS) in patients receiving erlotinib + celecoxib vs. erlotinib + placebo for advanced NSCLC.
SECONDARY OBJECTIVES:
I. Objective tumor response rate as defined by RECIST Criteria for subjects receiving erlotinib/celecoxib treatment arms.
II. Categorize the change in e-cadherin expression from baseline to week 8 in a subset of subjects.
III. Evaluation of overall survival (OS). IV. Measurement of COX-2, EGFR by immunohistochemistry and EGFR amplification by FISH, and EGFR mutation status to correlate with clinical response.
V. Measurement of change in urinary PGE-M and correlation with response.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
ARM II: Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
In both arms, treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I
Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
erlotinib hydrochloride
Given orally
placebo
Given orally
laboratory biomarker analysis
Correlative studies
immunohistochemistry staining method
Correlative studies
fluorescence in situ hybridization
Correlative studies
mutation analysis
Correlative studies
protein expression analysis
Correlative studies
gene expression analysis
Correlative studies
Arm II
Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
erlotinib hydrochloride
Given orally
celecoxib
Given orally
laboratory biomarker analysis
Correlative studies
immunohistochemistry staining method
Correlative studies
fluorescence in situ hybridization
Correlative studies
mutation analysis
Correlative studies
protein expression analysis
Correlative studies
gene expression analysis
Correlative studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
erlotinib hydrochloride
Given orally
celecoxib
Given orally
placebo
Given orally
laboratory biomarker analysis
Correlative studies
immunohistochemistry staining method
Correlative studies
fluorescence in situ hybridization
Correlative studies
mutation analysis
Correlative studies
protein expression analysis
Correlative studies
gene expression analysis
Correlative studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Available tumor tissue for mutation screening
* Measurable stage IIIb or IV disease by RECIST guidelines
* ECOG performance status of 0 or 1
* Progressive disease despite \>= 1 prior chemotherapy regimens as standard of care or subject's refusal or inability to receive standard chemotherapy
* Normal renal function (defined as serum creatinine =\< 2mg/dl)
* Normal liver function (defined as serum total bilirubin =\< 1.5, and serum transaminases =\< 2.5X the upper limits of normal \[ULN\]); if liver metastases are present, serum transaminases \> 5X the ULN
* No evidence of coagulopathy (defined as PT and/or PTT =\< 1.5X ULN or platelets \>= 100,000)
* No evidence of leukopenia (defined as absolute neutrophil count \>= 1,500 mm\^3)
* Negative pregnancy test prior to initiation of treatment and adequate contraception throughout treatment
Exclusion
* Cytotoxic chemotherapy agents within 4 weeks of initiating treatment; all toxicities must be recovered to baseline or NCI CTCAE v3.0 Grade 1 from all acute effects of prior cancer treatment, except alopecia or any clinically insignificant effect, prior to study initiation
* Evidence of NYHA class III or greater cardiac disease, history of myocardial infarction, cerebral vascular accident, symptomatic ventricular arrhythmia, or symptomatic conduction abnormality
* Non-cytoxic therapy within 2 weeks of initiating treatment ; all toxicities must be recovered to baseline or NCI CTCAE v3.0 Grade 1 from all acute effects of prior cancer treatment, except alopecia or any clinically insignificant effect, prior to study initiation
* Prior radiotherapy to target lesions is not permitted unless completed more than 4 weeks prior to treatment within the study and that there has been documented progression at these sites (Radiotherapy to non-target lesions is permitted within 2 weeks of study entry provided all acute effects of the radiotherapy have resolved at least grade 1)
* Comorbid disease or a medical condition that would impair the ability of the subject to receive or comply with the study protocol
* Prior malignancy within the last 3 years with the exception of non-melanoma skin cancer or cervical cancer in situ
* Hypersensitivity of erlotinib or celecoxib or to any of the excipients of these products
* Hypersensitivity to sulfonamides, aspirin or other NSAIDS
* Prior history of EGFR inhibitor for the treatment of cancer
* Previous history of gastrointestinal ulceration, bleeding or perforation
* Concurrent use of COX-2 inhibitors or other NSAIDS (For subjects on NSAIDS prior to study initiation, cessation of the drug for 72 hours prior to study entry is required)
* Chronic or concurrent use of steroids (topical steroids are acceptable if medically indicated)
* Subjects who require treatment with fluconazole or lithium
* Any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded)
* Renal insufficiency (defined as serum creatinine \> 2 mg/dl)
* Liver insufficiency (defined as serum total bilirubin \> 1.5, or serum transaminases \> 2.5C the upper limits of normal \[ULN\]); if liver metastases are present, serum transaminases \> 5X the ULN
* Coagulopathy (defined as PT and/or PTT \> 1.5X ULN or platelets \< 100,000)
* Leukopenia (defined as absolute neutrophil count \< 1,500/mm\^3)
* Pregnancy or inadequate contraception
* Lactating females
* Active CNS metastasis (stable, treated CNS metastasis acceptable)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OSI Pharmaceuticals
INDUSTRY
City of Hope Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen Reckamp
Role: PRINCIPAL_INVESTIGATOR
City of Hope Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope Medical Center
Duarte, California, United States
South Pasadena Cancer Center
South Pasadena, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2010-00353
Identifier Type: REGISTRY
Identifier Source: secondary_id
CDR0000549751
Identifier Type: REGISTRY
Identifier Source: secondary_id
06254
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.